Resumo

SILVA-CUEVAS, MA; APARICIO-HERNANDEZ, RM; SANCHEZ-LOPEZ, P  e  PRATS-OLIVAN, P. Positive assessment of drugs: from March, April, May, June and July of 2021. Sanid. Mil. [online]. 2021, vol.77, n.4, pp.211-217.  Epub 09-Maio-2022. ISSN 1887-8571.  https://dx.doi.org/10.4321/s1887-85712021000400008.

The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public from March to July of 2021, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product.

Palavras-chave : avalglucosidasa alfa (nexviadyme ^®); azacitidina (onureg ^®); azatioprina (jayempi ^®); duvelisib monohidrato (copiktra ^®); elivaldogen autotemcel (skysona ^®); estetrol/drospirenona (drovelis y lydisilka ^®); evinacumab (evkeeza ^®); hidrocortisona (efmody ^®); idecabtagene vicleucel (abecma ^®); imatinib (imatinib koanaa ^®); mesilato de tirbanibulina (klisyri ^®); odevixibat (bylvay ^®); pitolisant (ozawade ^®); ponesimod (ponvory ^®); relugolix/estradiol/acetato de noretisterona (ryeqo ^®); roxadustat (evrenzo ^®); satralizumab (enspryng ^®); selumetinib (koselugo ^®); setmelanotida (imcivree ^®); tafasitamab (minjuvi ^®); tralokinumab (adtralza ^®); vericiguat (verquvo ^®); vosoritida (voxzogo ^®)..

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )